BioLineRx (BLRX) Profit After Tax (2011 - 2026)

BioLineRx's Profit After Tax history runs 14 years deep, the most recent figure standing at -$2.2 million for Q4 2025.

• In Q4 2025, Profit After Tax rose 29.84% year-over-year to -$2.2 million; the TTM figure through Dec 2025 stood at $5.9 million (up 163.49% YoY), while the FY2025 annual figure was -$2.0 million, up 78.03% from the prior year.
• Profit After Tax for Q4 2025 stood at -$2.2 million, down from -$977000.0 in the prior quarter.
• The five-year high for Profit After Tax was $18.5 million in Q2 2023, with the low at -$16.0 million in Q3 2023.
• The 5-year median for Profit After Tax is -$3.7 million (2021), against an average of -$2.5 million.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax slumped 146.69% in 2023, then surged 836.64% in 2025.
• BioLineRx's Profit After Tax stood at -$4.3 million in 2021, then slumped by 33.16% to -$5.7 million in 2022, then sank by 142.26% to -$13.9 million in 2023, then soared by 77.05% to -$3.2 million in 2024, then advanced by 29.84% to -$2.2 million in 2025.
• Business Quant data shows BLRX's Profit After Tax at -$2.2 million in Q4 2025, -$977000.0 in Q3 2025, and $3.9 million in Q2 2025.